Updated weekly
Regulatory decisions, trial readouts, and safety findings — each with the primary source and an explanation of why it matters. We cover what changed, not what a vendor wants to sell.
Regulatory · 2026-08-10The single most consequential regulatory action in the peptide space was not a ban — it was a bulk-substance classification that quietly removed BPC-157, CJC-1295, ipamorelin, and thymosin alpha-1 from lawful US compounding.
The triple GIP/GLP-1/glucagon agonist has carried a ~24% Phase II weight-loss figure into Phase III, and the mechanistic addition of glucagon agonism is what makes the result interesting rather than merely larger.
Safety · 2026-07-15Mass-spectrometry analyses of consumer-purchased research peptides continue to report under-dosing, incorrect sequences, and endotoxin contamination in a meaningful fraction of samples.
Regulatory · 2026-06-30Schedule 4 and Schedule 10 classifications, criminal importation penalties, and an active sports-integrity apparatus make Australian peptide enforcement categorically different from US or European practice.
Research · 2026-06-12Roughly a quarter to two-fifths of weight lost on semaglutide or tirzepatide is lean tissue absent resistance training and adequate protein — proportionally similar to caloric restriction, but occurring at far greater total magnitude.
Industry · 2026-05-20Compounded semaglutide and tirzepatide were lawful only while the reference products sat on the FDA shortage list. Once resolved, that pathway closed, and enforcement shifted to telehealth marketers.
Regulatory · 2026-04-18Tested athletes have effectively no compliant peptide options outside approved therapeutic use exemptions: S0 covers any non-approved substance, and S2 covers growth factors and secretagogues.
Research · 2026-03-25Absorption enhancers such as SNAC, and newer small-molecule GLP-1 agonists, are eroding the injection requirement that has defined peptide therapeutics since insulin.
Verified wire
Newly surfaced studies, rulings and safety findings. Every entry was checked by an editor against its primary source before it appeared here.
A systematic review and meta-analysis investigated the impact of tirzepatide and semaglutide on blood pressure. This type of analysis synthesizes findings from multiple studies to provide a comprehensive view of the drugs' effects. Understanding these cardiovascular effects is important for patient management, especially for individuals with co-existing conditions like hypertension.
Source: EndocrineThis narrative review explores factors influencing persistence with GLP-1-based therapies in adults with obesity and type 2 diabetes. Persistence is crucial for achieving sustained weight loss and glycemic control in these patients. The review examines definitions of persistence, real-world outcomes, and determinants affecting long-term adherence to these treatments.
Source: Curr Diab RepA study investigated the relationship between endogenous Thymosin-α-1 (Tα1) plasma levels and COVID-19 severity in unvaccinated individuals. Researchers found that subjects who experienced moderate to severe SARS-CoV-2 infection had significantly lower circulating Tα1 plasma levels compared to those with asymptomatic or mild infection, one to two months post-diagnosis. This suggests a potential immunomodulatory role for Tα1 in the host response to SARS-CoV-2 and may inform future research on therapeutic strategies.
Source: Scientific Reports (Nature Publishing Group)Holland & Knight issued an alert outlining key legal and regulatory considerations for companies acquiring businesses in the peptide and wellness sector. The alert highlights the complex and evolving regulatory landscape, emphasizing potential enforcement risks related to product classification, compounding, state licensing, and marketing claims. Acquirers are advised to conduct thorough due diligence and incorporate specific risk-allocation mechanisms in transaction documents.
Source: Holland & KnightA real-world analysis of 13,507 Mochi Health patients found an average body weight loss of 11.5% at six months, with 59.1% achieving at least 10% total body weight loss. Tirzepatide demonstrated a significantly higher response rate for weight loss compared to semaglutide, even after controlling for patient differences. This observational study highlights the outcomes seen in everyday care, which are typically lower than those reported in clinical trials due to shorter duration and varying medication adherence.
Source: Mochi Health (citing medRxiv preprint)A study using federated electronic health records found that GLP-1-based incretin therapy was associated with a lower incidence of Alzheimer's disease and cardiorenal events. The research involved over 153,000 adults aged 50 or older with AD risk factors. This suggests potential protective effects of GLP-1 therapies beyond glucose control, indicating broader therapeutic applications.
Source: Biol Methods ProtocA systematic review examined GLP-1RA-based combination strategies for weight loss, including single-agent multi-target agonists and multi-drug combination therapies. These approaches, such as dual GLP-1R/GIPR or GLP-1R/GCGR agonists, demonstrate greater weight loss and potential improvements in hepatic and cardiovascular metabolism compared to single-target GLP-1RAs. While gastrointestinal events are common, increasing targets and doses may warrant attention to potential risks like elevated heart rate and hypoglycemia.
Source: Pharmacological ResearchThe FDA's Pharmacy Compounding Advisory Committee (PCAC) recommended adding six out of seven reviewed peptides to the 503A Bulks List for compounding. This recommendation would allow these peptides to be lawfully compounded under Section 503A of the FD&C Act. However, FDA staff opposed the additions, citing insufficient evidence of safety and effectiveness, lack of human clinical trial data, and potential safety concerns.
Source: Kelley Drye & Warren LLPAn independent advisory committee to the U.S. FDA narrowly voted to recommend allowing specialized pharmacies to compound four specific peptides. This decision contrasts with FDA scientists' arguments that there is insufficient clinical data to support the peptides' efficacy and unknown health risks. The FDA is not obligated to follow this recommendation and will issue a final decision in the coming weeks.
Source: ScienceAn FDA advisory committee voted to recommend easing restrictions on BPC-157, a peptide currently popular among wellness influencers but lacking FDA approval. This recommendation is the first of several peptides being reviewed by the committee. The final decision rests with the FDA itself.
Source: NBC NewsThe U.S. Food and Drug Administration (FDA) is reportedly evaluating several peptides for specific therapeutic applications. These applications include the treatment of ulcerative colitis, insomnia, and osteoporosis. This evaluation indicates a potential pathway for new peptide-based therapies in these areas, though commercial marketing often extends beyond approved uses.
Source: New York TimesA U.S. Food and Drug Administration (FDA) advisory panel narrowly recommended easing restrictions on several peptides, including BPC-157, TB-500, and KPV, for pharmacy compounding. This vote, while not binding, advises the agency to remove current restrictions that bar pharmacies from producing injectable forms of these peptides. The decision comes despite warnings from FDA scientists about the lack of safety and efficacy data for these substances.
Source: PBS NewsHourThe FDA's Pharmacy Compounding Advisory Committee is scheduled to meet on July 23-24 to assess whether seven peptides, including BPC-157, TB-500, and Semax, should be eligible for compounding under federal law. This review comes as these peptides gain popularity for various health claims despite a notable lack of robust human clinical evidence for their safety or efficacy. FDA scientists have already recommended against allowing their compounding due to insufficient data, and concerns about potential committee member bias have been raised.
Source: ForbesA national poll commissioned by Peppies.com found that 52% of Americans believe peptides should be obtainable through licensed U.S. pharmacies with a doctor's prescription. Only 3% opposed this pathway, with 45% undecided. The findings were released ahead of an FDA Pharmacy Compounding Advisory Committee meeting concerning the lawful compounding pathway for seven peptides.
Source: PR Newswire (via Morningstar)A new national survey indicates that 52% of U.S. adults believe peptides should be obtainable through licensed pharmacies with a doctor's prescription, with only 3% opposing this pathway. The poll highlights a preference for preventive medicine and patient health outcomes guiding medication legality. These findings emerge as the FDA's Pharmacy Compounding Advisory Committee is set to discuss whether seven peptides should regain a lawful compounding pathway.
Source: PR Newswire (via Yahoo Finance)This review explores dual incretin therapy as an advanced strategy for patients with metabolic conditions who have reached therapeutic plateaus or experienced failure with GLP-1 monotherapy. It examines how combining GLP-1 receptor agonists with other incretin-based therapies can achieve greater metabolic synergy, offering improved glycemic control and weight loss outcomes. The review highlights the rationale and potential benefits of escalating treatment to dual incretin approaches.
Source: CureusOne email. Regulatory changes, new trial data, and safety findings.